Greenberg Traurig is extremely proud to represent Redhill Biopharma with the recent announcement of providing an initial update on the compassionate use program with its investigational drug, opaganib, in patients with confirmed SARS-CoV-2 infection (COVID-19) in Israel.

RedHill Biopharma is a longstanding client of GT’s Barry Schindler, Chair of Greenberg Traurig’s Global Patent Prosecution…